{
    "nctId": "NCT03006172",
    "briefTitle": "To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",
    "officialTitle": "A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 256,
    "primaryOutcomeMeasure": "Stage 1: Percentage of Participants With Dose Limiting Toxicities",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Evaluable or measurable disease per RECIST, Version 1.1 (measurable disease only for Arm D)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Life expectancy of greater than or equal to (\\>=) 12 weeks\n* Adequate hematologic and organ function, including blood counts, liver and kidney function\n\nStage I Arm A (Inavolisib):\n\n- Locally advanced, recurrent, or metastatic, PIK3CA mutant, incurable solid tumor malignancy, including breast cancer\n\nStages I and II, Arms B and C:\n\n- Postmenopausal female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer\n\nStage II, Arms D, E, or F:\n\n- Female participants with locally advanced or metastatic PIK3CA-mutant HR+/HER2- breast cancer\n\nStage II Arm D:\n\n- Prior treatment with CDK4/6 inhibitor\n\nStage II Arm G:\n\n* Female participants with locally advanced or metastatic PIK3CA-mutant HER2+ breast cancer\n* Left ventricular ejection fraction 50% or greater\n\nStages I and II:\n\n- All participants must provide tumor tissue from the primary or metastatic tumor site obtained from a prior or new biopsy or surgical procedure for detection of PIK3CA mutation by central laboratory test.\n\nExclusion Criteria:\n\n* Metaplastic breast cancer\n* History of leptomeningeal disease\n* Type 1 or 2 diabetes requiring anti-hyperglycemic medication\n* Inability or unwillingness to swallow pills\n* Malabsorption syndrome or other condition that would interfere with enteral absorption\n* Known and untreated, or active central nervous system metastases\n* Uncontrolled pleural effusion or ascites\n* Any active infection that could impact patient safety or serious infection requiring intravenous antibiotics\n* History of other malignancy within 5 years, except for treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer\n* History of or active ventricular dysrhythmias or congestive heart failure requiring medication or symptomatic coronary heart disease\n* Congenital long QT syndrome, prolonged QT interval, or family history of sudden unexplained death or long QT syndrome\n\nStage II Arms B, C, D, and E only:\n\n* Prior treatment with \\>1 chemotherapy regimen for metastatic disease\n* Prior treatment with PI3K inhibitor\n* History of significant toxicity related to mTOR inhibitor requiring treatment discontinuation\n\nStage II Arms B and E only:\n\n- Prior CDK4/6 inhibitor treatment\n\nStage II Arm G only:\n\n* Current uncontrolled hypertension or unstable angina\n* History of congestive heart failure, serious cardiac arrhythmia, or recent myocardial infarction\n* Prior ejection fraction decrease on trastuzumab\n* Prior cumulative doxorubicin greater than 360 mg/m2\n* Symptomatic active lung disease\n* History of significant toxicity related to trastuzumab and/or pertuzumab requiring discontinuation of treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}